title: National, state, and selected local area vaccination coverage among children aged 19-35 months - United States, 2013.
abstract: In the United States, among children born during 1994-2013, vaccination will prevent an estimated 322 million illnesses, 21 million hospitalizations, and 732,000 deaths during their lifetimes. Since 1994, the National Immunization Survey (NIS) has monitored vaccination coverage among children aged 19-35 months in the United States. This report describes national, regional, state, and selected local area vaccination coverage estimates for children born January 2010-May 2012, based on results from the 2013 NIS. In 2013, vaccination coverage achieved the 90% national Healthy People 2020 target for ≥ 1 dose of measles, mumps, and rubella vaccine (MMR) (91.9%); ≥ 3 doses of hepatitis B vaccine (HepB) (90.8%); ≥ 3 doses of poliovirus vaccine (92.7%); and ≥ 1 dose of varicella vaccine (91.2%). Coverage was below the Healthy People 2020 targets for ≥ 4 doses of diphtheria, tetanus, and pertussis vaccine (DTaP) (83.1%; target 90%); ≥ 4 doses of pneumococcal conjugate vaccine (PCV) (82.0%; target 90%); the full series of Haemophilus influenzae type b vaccine (Hib) (82.0%; target 90%); ≥ 2 doses of hepatitis A vaccine (HepA) (54.7%; target 85%); rotavirus vaccine (72.6%; target 80%); and the HepB birth dose (74.2%; target 85%). Coverage remained stable relative to 2012 for all of the vaccinations with Healthy People 2020 objectives except for increases in the HepB birth dose (by 2.6 percentage points) and rotavirus vaccination (by 4.0 percentage points). The percentage of children who received no vaccinations remained below 1.0% (0.7%). Children living below the federal poverty level had lower vaccination coverage compared with children living at or above the poverty level for many vaccines, with the largest disparities for ≥ 4 doses of DTaP (by 8.2 percentage points), full series of Hib (by 9.5 percentage points), ≥ 4 doses of PCV (by 11.6 percentage points), and rotavirus (by 12.6 percentage points). MMR coverage was below 90% for 17 states. Reaching and maintaining high coverage across states and socioeconomic groups is needed to prevent resurgence of vaccine-preventable diseases.
authors.forename: Laurie D
authors.initials: LD
authors.lastname: Elam-Evans
authors.forename: David
authors.initials: D
authors.lastname: Yankey
authors.forename: James A
authors.initials: JA
authors.lastname: Singleton
authors.forename: Maureen
authors.initials: M
authors.lastname: Kolasa
mesh_terms: D017677:Age Distribution; D016667:Bacterial Capsules; D019433:Chickenpox Vaccine / Q000008:administration & dosage; D002675:Child, Preschool; D004196:Disease Outbreaks / Q000517:prevention & control*; D005006:Ethnicity / Q000706:statistics & numerical data; D005260:Female; D018073:Haemophilus Vaccines / Q000008:administration & dosage; D022362:Hepatitis A Vaccines / Q000008:administration & dosage; D017325:Hepatitis B Vaccines / Q000008:administration & dosage; D006801:Humans; D007223:Infant; D017053:Infection Control / Q000706:statistics & numerical data*; D008297:Male; D010567:Pertussis Vaccine / Q000008:administration & dosage; D011159:Population Surveillance; D011203:Poverty / Q000706:statistics & numerical data; D012411:Rubella Vaccine / Q000008:administration & dosage; D012959:Socioeconomic Factors; D014481:United States / Q000453:epidemiology; D014611:Vaccination / Q000706:statistics & numerical data*
chemical_list: D019433:Chickenpox Vaccine; D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D022362:Hepatitis A Vaccines; D017325:Hepatitis B Vaccines; D010567:Pertussis Vaccine; D012411:Rubella Vaccine